Summary & Overview

HCPCS Level II J7639: Dornase Alfa Inhalation Solution, DME Unit Dose

HCPCS Level II code J7639 represents dornase alfa, an FDA-approved inhalation solution supplied as a non-compounded, unit dose product and billed per milligram. This code is used when dornase alfa is dispensed and administered through durable medical equipment, typically in home or outpatient settings. Nationally, accurate use of J7639 matters for clinical continuity in cystic fibrosis and other inhalation-therapy indications, for claims processing, and for consistent drug reimbursement across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of what the code represents, common billing contexts, payer coverage considerations, and where to expect benchmarks or policy updates. The publication outlines clinical context for inhaled mucolytic therapy and summarizes typical service lines and sites of service tied to DME-based administration.

Where specific input data is absent, the publication notes: "Data not available in the input." The content focuses on national implications for billing and coding practice, payer inclusion, and practical reference for providers, coders, and policy analysts seeking an authoritative overview of HCPCS Level II code J7639.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7639HCPCS Level IIdornase alfainhalation therapydurable medical equipmentunit dosedrug billingDME administration

Billing Code Overview

HCPCS Level II code J7639 describes dornase alfa, an inhalation solution provided as an FDA-approved final, non-compounded product in unit dose form and billed per milligram. The service type is medication administration via durable medical equipment (DME), where the drug is supplied in a unit dose for inhalation therapy.

The typical site of service for J7639 is home or outpatient settings where DME is used, including patient residences when inhalation therapy is administered through DME devices. Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient receiving J7639 is a pediatric or adult patient with cystic fibrosis who requires inhaled dornase alfa (recombinant human DNase) to reduce airway mucus viscosity and improve pulmonary clearance. The medication is provided as an FDA-approved, unit-dose inhalation solution, supplied and administered through durable medical equipment (DME) such as a nebulizer. A realistic scenario: a 12-year-old with cystic fibrosis presents for routine pulmonary follow-up with increased productive cough and sputum retention; the pulmonologist prescribes daily nebulized dornase alfa to be dispensed by the DME supplier. The DME provider coordinates delivery of unit-dose vials, trains the patient/caregiver on nebulizer use and storage, documents medication administration or patient education in the DME record, and files claims using J7639 per milligram for the dispensed medication. Typical workflow steps: clinician documents indication and orders the medication; prescription is sent to DME supplier; DME verifies coverage, supplies unit-dose vials and compatible nebulizer if needed, provides patient education and documentation, and bills payors using J7639 with appropriate modifiers and corresponding diagnosis codes for cystic fibrosis or other qualifying pulmonary conditions.

Coding Specifications

Modifier	Description	When to Use
`11`	Provider is the primary surgeon/performer	Use when the billing practitioner is the primary provider responsible for the service on the claim (rare for DME-supplied drugs but applicable if furnished by a treating clinician).
`22`	Increased procedural services	Use when substantially greater services are provided (e.g., extensive patient education or complex device setup beyond typical time).
`52`	Reduced services	Use when less than the full service is provided (partial vial or abbreviated teaching session documented).
`53`	Discontinued procedure	Use if therapy was started but discontinued due to patient intolerance or adverse reaction before completion of planned administration.
`54`	Surgical care only	Not commonly used for DME drug supply; included when split/shared surgical billing applies alongside other services.
`55`	Postoperative management only	Not typically applicable but available if only postoperative drug supply is billed separate from surgical claim.
`62`	Two surgeons	Rarely applicable; use when two qualified providers share responsibility for the procedure.
`78`	Unplanned return to the OR by the same physician following initial procedure	Not applicable to routine DME drug supply but included when emergent procedural interventions occur.
`80`	Assistant surgeon	Use when an assistant surgeon is billing in conjunction with a primary surgeon; rarely applies to DME drug supply.
`82`	Assistant surgeon (when a qualified resident surgeon is unavailable)	As above; seldom used for `J7639` but included for completeness.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Rare for this drug but used when qualifying advanced practitioner assists in a procedure where the drug is administered.
`CQ`	Service delivered under an oral or parenteral chemotherapy administration when performed in the home (DME context)	Use when applicable programmatic rules treat the infusion or home-administered specialty drug similarly — document per payor requirements.
`QX`	Modifier certifying services furnished by an operating qualified individual	Use when required to indicate a certified clinician provided the service.
`QY`	Intrafacility service rendered under supervision of another provider	Use where supervision and billing distinctions are necessary under facility rules.

Taxonomy Code	Specialty	Notes
`207RP0000X`	Pulmonology	Pulmonologists diagnose and order inhaled dornase alfa for cystic fibrosis and other severe mucus-retention disorders.
`208000000X`	Pediatrics	Pediatricians commonly manage children with cystic fibrosis and coordinate outpatient prescriptions and DME supply.
`3336C0002X`	Respiratory Care	Respiratory therapists and DME respiratory suppliers provide nebulizer training, device setup, and patient education.
`207L00000X`	Allergy & Immunology	Allergy/immunology specialists may co-manage airway clearance in select patients with chronic sputum disorders.
`261QM2500X`	Durable Medical Equipment & Medical Supplies	DME suppliers and durable medical equipment providers bill and dispense `J7639` and associated nebulizer equipment.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E84.0`	Cystic fibrosis with pulmonary manifestations	Primary indication for inhaled dornase alfa to reduce sputum viscosity and improve clearance.
`E84.11`	Cystic fibrosis with pulmonary manifestations, pulmonary infection	Active or recurrent pulmonary infection in cystic fibrosis patients often necessitates airway clearance therapy including dornase alfa.
`J98.01`	Acute bronchospasm	Nebulized mucolytics and airway therapies may be part of the management when mucus plugging contributes to bronchospasm.
`J44.9`	Chronic obstructive pulmonary disease, unspecified	In select COPD patients with significant mucus hypersecretion, mucolytic strategies may be considered; dornase alfa use is uncommon and off-label but occasionally documented.
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Higher-acuity patients receiving inhaled therapies via DME in the home or facility may have respiratory failure necessitating careful monitoring and documentation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes, nebulizer; initial and each additional	Performed when a clinician administers or supervises nebulized medication delivery in clinic; relates to in-office inhalation treatments that mirror home nebulizer use of dornase alfa.
`94010`	Spirometry, including graphic plot; complete, with interpretation and report	Pulmonary function testing commonly performed before or during therapy to assess baseline and response to dornase alfa.
`94760`	Noninvasive ear or transcutaneous monitoring of carbon dioxide (e.g., capnography) for evaluation of ventilatory status	Used in higher-acuity settings when nebulized therapies are given to monitor respiratory status.
`96160`	Administration of patient-focused health risk assessment instrument (e.g., depression screening)	Relevant when comprehensive patient education and assessments are documented as part of DME instruction and adherence evaluation.
`99070`	Supplies and materials (except spectacles), non-covered items, used during patient care, list separately in addition to procedure code	May be used by DME suppliers to bill for additional supplies related to nebulizer use when payor rules permit.